State Board of Administration of Florida Retirement System acquired a new position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) during the second quarter, HoldingsChannel reports. The institutional investor acquired 14,530 shares of the biopharmaceutical company’s stock, valued at approximately $178,000.
Several other institutional investors also recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in Dicerna Pharmaceuticals in the first quarter valued at $102,000. Quantitative Systematic Strategies LLC purchased a new position in Dicerna Pharmaceuticals in the first quarter valued at $113,000. Caxton Corp purchased a new position in Dicerna Pharmaceuticals in the first quarter valued at $125,000. Jane Street Group LLC purchased a new position in Dicerna Pharmaceuticals in the first quarter valued at $136,000. Finally, Verition Fund Management LLC purchased a new position in Dicerna Pharmaceuticals in the first quarter valued at $141,000. 87.02% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:DRNA opened at $14.81 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.40 and a current ratio of 5.40. Dicerna Pharmaceuticals Inc has a 12 month low of $3.41 and a 12 month high of $17.50. The firm has a market capitalization of $841.90 million, a P/E ratio of -4.05 and a beta of 2.43.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.79 million. analysts predict that Dicerna Pharmaceuticals Inc will post -1.14 EPS for the current fiscal year.
In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 2,301 shares of the company’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $17.50, for a total value of $40,267.50. Following the completion of the transaction, the insider now owns 26,781 shares in the company, valued at $468,667.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total transaction of $232,496.00. Following the completion of the transaction, the director now owns 29,064 shares of the company’s stock, valued at approximately $465,024. The disclosure for this sale can be found here. Corporate insiders own 19.85% of the company’s stock.
Several equities analysts recently commented on the company. BidaskClub raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 10th. ValuEngine lowered Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 2nd. SunTrust Banks increased their target price on Dicerna Pharmaceuticals to $20.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright raised Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Wednesday, August 15th. Finally, Cowen reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $15.54.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Read More: What is the NASDAQ?
Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.